Final Results

RNS Number : 0169Q
Renishaw PLC
28 July 2010
 



 

RENISHAW plc

 

New Mills, Wotton-under-Edge

Gloucestershire GL12 8JR

United Kingdom

 

Tel          +44 (0) 1453 524524

Fax         +44 (0) 1453 524901

Email      uk@renishaw.com

 

www.renishaw.com

 

 

28th July 2010

 

Renishaw plc and subsidiary undertakings

Preliminary announcement of results for the year ended 30th June 2010

 

 

 

HIGHLIGHTS

 


2010

2009

change





Revenue (£m)

181.6

171.2

+6%





Adjusted operating profit (£m)*

28.1

6.0

+368%





Adjusted profit before tax (£m)*

28.7

8.8

+226%





Adjusted earnings per share (pence)*

31.6

9.3

+240%





Dividend per share (pence)

17.6

7.76

+127%





STATUTORY








Profit before tax (£m)

27.1

4.7

+477%





Basic earnings per share (pence)

29.3

4.9

+498%

 

* Adjusted figures are stated after excluding exceptional items, these being an impairment write-down in 2010 and redundancy costs in 2009.

 

 

 

 

CHAIRMAN'S STATEMENT

 

I am very pleased to announce the results for the year to 30th June 2010. This year has been characterised by a welcome return to growth, with an accelerating order intake culminating in record final quarter sales.

 

Operating results

 

Revenues continued to increase strongly during the second half of the year and amounted to a 57% increase over the comparable period in 2009 and 46% over revenues in the first half of the year. This was supported by a superb performance by our manufacturing teams. Total revenues for the year were £181.6m (2009 £171.2m), which includes a currency benefit of £8.1m when compared with the previous year's exchange rates. 

 

Geographically, there was a comparative reduction in turnover in continental Europe and the UK, but modest growth in the Americas and particularly strong growth in the Far East, largely China, and other territories, including India. 

 

After reporting a first half year operating profit of £6.9m (2009 £11.9m), Group operating profit for the year was £28.1m (2009 £6.0m) before an exceptional deduction of £1.7m for impairment costs of the investment in associates. 

 

Profit before tax, including £6.8m currency benefit, amounted to £27.1m compared with £4.7m for the previous year and profit after tax was £21.3m (2009 £3.6m) resulting in earnings per share of 29.3p (2009 4.9p). Adjusted earnings per share, which excludes the exceptional impairment write-down this year and redundancy costs last year, were 31.6p, compared with 9.3p last year. 

 

 

Segmental analysis

 

As reported at the half year, the Group has divided its operating, research and development and reporting activities into two main segments: the traditional Metrology business, the cornerstone of Renishaw, and, more recently, the as yet smaller Healthcare activities into which parts of Renishaw have migrated or which have been established or acquired.

 

(1)           Metrology

               

Metrology revenue grew to £162.1m from £152.9m in 2009, with operating profits, prior to exceptional items, of £31.5m compared with £10.3m in 2009. Particular growth was experienced in the Far East and, in terms of products, there was strong demand for our encoder and laser scale products.

 

This sector continues to invest heavily in development of new products. Research and Development, including associated engineering costs, was £22.0m (2009 £26.2m).

 

This year has seen the introduction of a number of new products including the QC20-W wireless Ballbar for checking the servo-ing performance of three-axis machine tools; the RMP40, RLP40 and OLP40 compact probes with radio and optical signal transmissions for multi-axis and mill-turn machine tools and lathes; and the PH20 probe head for co-ordinate measuring machines was successfully launched at the Control Show in Germany in May. The TONIC™ range of encoders and RESOLUTE™ absolute encoders have also been enthusiastically received by the market.

 

On 23rd July 2010 the Group acquired a 29% shareholding in Measurement Devices Limited (MDL) for the sum of £2.3m. An agreement provides for the further purchase of the balance of the shares over a period of four years. MDL is a metrology company based in York, with offices in Aberdeen and USA (Houston). Its laser scanner products are primarily marketed in the areas of marine positioning and mine/quarry scanning. MDL's products will add to Renishaw's current range of laser-based products and the Group's investment in MDL will enable MDL to expand further on a global basis and benefit from Renishaw's technology, engineering and manufacturing expertise and worldwide distribution network.

 

(2)           Healthcare

 

The Healthcare segment comprises the neurosurgical, dental and spectroscopy products, which includes PulseTeq (head coils for the enhancement of MRI images), Renishaw Diagnostics (molecular diagnostics for the early identification of infectious diseases) and Renishaw Mayfield (neurosurgical robots).

 

Revenue in this sector for the year amounted to £19.5m (2009 £18.4m) which resulted in an operating loss of £3.4m, compared with a loss of £4.3m in the previous year.

 

Research and Development in this sector amounted to £6.6m (2009 £7.5m) and was focussed on developing the expanding range of Healthcare offerings. Significant resource and expenditure has been directed to addressing very demanding regulatory compliance regulations associated with the global supply of healthcare and medical devices.

 

The Group has recently entered into an agreement with a world leading dental implant company, Biomet 3i LLC, for the development and marketing of comprehensive digital dental solutions to dental professionals and patients worldwide. The collaboration will see Biomet 3i marketing Renishaw dental scanners, in-lab milling machines and dental 3i incise CAD software to dental laboratories through its global marketing and sales organisation. Crown and bridge dental frameworks in zirconia and cobalt chrome (cobalt chrome initially available in Europe only) will be manufactured and supplied through a collaboration between both companies.

 

Spectroscopy product revenue, presently the largest part of our healthcare revenue, continued to show good growth, especially in the Far East.

 

Balance sheet

 

Capital expenditure for the year was £2.9m (2009 £11.0m). The Group is currently concluding the fitting out of production facilities at Pune in India, expected to be completed by December 2010 at a cost of around £3m. In addition, the refurbishment (estimated to cost £1.8m) of the recently acquired premises in Charfield, close to New Mills in Gloucestershire, UK, has commenced. These will be occupied by our dental and medical activities early in 2011.

 

Further investment has been made in a number of new machine tools at our Stonehouse factory. At the Woodchester facility, investment that will double the capacity of automated surface-mount electronics assembly and automation of stylus assembly processes are currently being commissioned.

 

Working capital (accounts receivable plus inventories less creditors) has grown by a net £12m reflecting the significantly increased level of activity, particularly in the final quarter. 

 

Year end net cash balances amounted to £31.1m (2009 £20.5m).

 

Despite an improving investment performance, the deficit in the pension fund (which has been closed to future accrual since 2007) has increased to £37.3m (£22.5m at 30th June 2009) reflecting changes in the actuarial assumptions used, in particular, a significant reduction in the discount rate and a change to the mortality assumption adopted (reflecting the increasing life expectancy). The Company has a recovery plan to fund the deficit no later than 30th September 2016 and is reviewing the recovery plan with the trustees following the 30th September 2009 triennial actuarial valuation.

 

Staff

 

I am very grateful to all our employees worldwide for their loyalty and commitment, especially after the unprecedented difficulties and challenges which were successfully overcome last year.

 

I now look forward to a more stable business environment in which our employees will continue to play a full and important part in generating a prosperous future for the Company.

 

Directors

 

In line with the UK Corporate Governance Code, all the directors are standing for re-election at the annual general meeting, with the exception of Joe McGeehan. Joe has been a director since January 2001 and having completed nine years service, latterly as the senior independent director, will not be seeking re-election. Joe has contributed enormously to the activities of the Board during his period of appointment and his commitment has been valued greatly. On behalf of the Board, I should like to thank Joe for his efforts and contribution to Renishaw.

 

Bill Whiteley has been appointed the senior independent director with effect from 26th July 2010.

 

Dividend

 

Your directors are recommending a final dividend of 13.6p per share, giving a total dividend for the year of 17.6p, compared with 7.76p in 2009 (covered 1.8 times by adjusted earnings per share for the year) payable on 18th October 2010 to shareholders on the share register on 17th September 2010.

 

Prospects

 

It is clear from the strong second half performance that the Company is showing real momentum going into the new financial year, highlighted by our record order book for the start of a new year of £23.3m, compared with £9.7m at the start of the previous year.

 

Whilst economic uncertainties remain, we have a robust international business model that continues to spread its applications into new markets. Our particular optimism for further developments in the expanding range of healthcare offerings, together with our continued investment in new products in our traditional markets, underpins our confidence in future growth.

 

 

 

Sir David R McMurtry, CBE, RDI, FREng, CEng, FIMechE

Chairman & Chief Executive

28th July 2010

 

 

 

 

 

 

CONSOLIDATED INCOME STATEMENT

for the year ended 30th June 2010

 



2010

2009



£'000

£'000





Revenue


181,607

171,247





Cost of sales


(93,832)

(101,064)

 




Gross profit


87,775

70,183





Distribution costs


(39,742)

(41,559)

 




Administrative expenses including exceptional item


(21,606)

(26,754)

 




Operating profit excluding exceptional item


28,095

5,991

 




Exceptional items: 2010 - impairment write-down; 2009 - redundancy costs


(1,668)

(4,121)

 




Operating profit


26,427

1,870





Financial income


5,926

8,754

 




Financial expenses


(5,775)

(6,219)

 




Share of profits of associates


479

317

 




Profit before tax


27,057

4,722





Income tax expense


(5,745)

(1,124)

 




Profit for the year from continuing operations


21,312

3,598

 

 

Profit attributable to:


2010

2009



£'000

£'000





Equity shareholders of the parent company


21,814

3,871

Non-controlling interest


(502)

(273)





Profit for the year from continuing operations


21,312

3,598

 



pence

pence





Dividend per share in respect of the year


17.6

7.76





Dividend per share paid in the year


4.0

25.39





Earnings per share (basic and diluted)


29.3

4.9

 

 

  

 

 

 

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME AND EXPENSE

for the year ended 30th June 2010

 



2010

2009



£'000

£'000





Profit for the year


21,312

3,598





Foreign exchange  translation differences


2,201

248





Actuarial loss in the pension schemes


(14,867)

(13,032)





Effective portion of changes in fair value of cash flow




Hedges, net of recycling:


7,760

(1,615)





Comprehensive income and expense of associates


(324)

-





Deferred tax on income and expense recognised in equity


1,820

3,614





Expense recognised directly in equity


(3,410)

(10,785)





Total comprehensive income and expense for the year


17,902

(7,187)





Attributable to:




Equity shareholders of the parent company


18,404

(6,914)

Non-controlling interest


(502)

(273)





Total comprehensive income and expense for the year


17,902

(7,187)

 

 

  

 

 

 

 

CONSOLIDATED BALANCE SHEET

at 30th June 2010

 



2010

2009



£'000

£'000





Assets




Property, plant and equipment


70,532

73,583

Intangible assets


28,613

27,683

Investments in associates


5,152

7,085

Deferred tax assets


20,056

14,165

Derivatives


4,002

4,020





Total non-current assets


128,355

126,536





Current assets




Inventories


30,884

29,156

Trade receivables


45,873

24,057

Current tax


1,848

1,626

Other receivables


4,725

3,626

Derivatives


1,158

709

Cash and cash equivalents


31,143

20,488





Total current assets


115,631

79,662





Current liabilities




Trade payables


10,440

6,588

Current tax


532

910

Provisions


539

656

Derivatives


3,346

5,623

Other payables


15,027

7,716





Total current liabilities


29,884

21,493





Net current assets


85,747

58,169





Non-current liabilities




Employee benefits


37,251

22,458

Deferred tax liabilities


15,433

10,618

Derivatives


1,575

6,627

Other payables


1,222

1,222





Total non-current liabilities


55,481

40,925





Total assets less total liabilities


158,621

143,780





Equity




Share capital


14,558

14,558

Share premium


42

42

Currency translation reserve


4,023

1,822

Cash flow hedging reserve


172

(5,415)

Retained earnings


140,459

132,755

Other reserve


(201)

-

Non-controlling interest


(432)

18





Total equity


158,621

143,780

 

 

 

  

 

 

 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the year ended 30th June 2010

 





Cash








Currency

flow



Non-



Share

Share

translation

hedging

Retained

Other

controlling



capital

premium

reserve

reserve

earnings

Reserve

Interest

Total

Year ended 30th June 2009

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000









14,558

42

1,574

(4,252)

154,403

-

320

166,645









-

-

-

-

3,871

-

(273)

3,598









Other comprehensive income and expense:









-

-

-

-

(9,870)

-

-

(9,870)









-

-

248

-

-

-

-

248









-

-

-

(1,163)

-

-

-

(1,163)









-

-

248

(1,163)

(9,870)

-

-

(10,785)









Total comprehensive income

-

-

248

(1,163)

(5,999)

-

(273)

(7,187)









-

-

-

-

-

-

(29)

(29)









-

-

-

-

(15,649)

-

-

(15,649)









-

-

-

-

(15,649)

-

(29)

(15,678)









Balance at 30th June 2009

14,558

42

1,822

(5,415)

132,755

-

18

143,780









Year ended 30th June 2010

















-

-

-

-

21,814

-

(502)

21,312









Other comprehensive income and expense:









-

-

-

-

(10,874)

-

-

(10,874)









-

-

2,201

-

-

-

-

2,201









-

-

-

5,587

-

-

-

5,587









-

-

-

-

(324)

-

-

(324)









-

-

2,201

5,587

(11,198)

-

-

(3,410)









Total comprehensive income

-

-

2,201

5,587

10,616

-

(502)

17,902









-

-

-

-

-

(201)

52

(149)









-

-

-

-

(2,912)

-

-

(2,912)









-

-

-

-

(2,912)

(201)

52

(3,061)









Balance at 30th June 2010

14,558

42

4,023

172

140,459

(201)

(432)

158,621

 

 

 

 

 

 

CONSOLIDATED STATEMENT OF CASH FLOW

for the year ended 30th June 2010

 



2010

2009



£'000

£'000

Cash flows from operating activities




Profit for the year


21,312

3,598





Adjustments for:




Amortisation of development costs


4,692

4,433

Amortisation of other intangibles


1,871

1,441

Depreciation


7,907

8,890

(Profit)/loss on sale of property, plant and equipment


(31)

151

Share of profits from associates


(479)

(317)

Exceptional impairment write-down


1,668

-

Financial income


(5,926)

(8,754)

Financial expenses


5,775

6,219

Tax expense


5,745

1,124







21,222

13,187





(Increase)/decrease in inventories


(1,728)

5,064

(Increase)/decrease in trade and other receivables


(21,252)

28,167

Increase/(decrease) in trade and other payables


10,711

(12,026)

(Decrease) in provisions


(117)

(168)







(12,386)

21,037





Income taxes paid


(5,615)

(6,368)





Cash flows from operating activities


24,533

31,454





Investing activities




Purchase of property, plant and equipment


(2,868)

(11,005)

Development costs capitalised


(6,968)

(6,618)

Purchase of other intangibles


(184)

(7,503)

Investment in subsidiaries and associates


(149)

(400)

Sale of property, plant and equipment


190

259

Interest received


255

1,161

Dividend received from associate


80

80





Cash flows from investing activities


(9,644)

(24,026)

 




Financing activities




Interest paid


(178)

(255)

Dividends paid


(2,912)

(15,649)





Cash flows from financing activities


(3,090)

(15,904)





Net increase/(decrease) in cash and cash equivalents


11,799

(8,476)

 




Cash and cash equivalents at beginning of the year


20,488

38,183





Effect of exchange rate fluctuations on cash held


(1,144)

(9,219)





Cash and cash equivalents at end of the year


31,143

20,488

 

 

 

 

STATUS OF THIS PRELIMINARY ANNOUNCEMENT

 

The financial information set out above does not constitute the Company's statutory accounts for the years ended 30th June 2010 or 2009 but is derived from those accounts. Statutory accounts for 2009 have been delivered to the registrar of companies, and those for 2010 will be delivered in due course. The auditors have reported on those accounts; their reports were (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report and (iii) did not contain a statement under section 498 (2) or (3) of the Companies Act 2006.

 

This preliminary announcement and the presentation of results will be available on the Company's website www.renishaw.com.

 

 

 

NOTES TO THE FINANCIAL STATEMENTS

 

1. Accounting policies

Basis of preparation

Renishaw plc (the "Company") is a company incorporated in the UK.

The group financial statements consolidate those of the Company and its subsidiaries (together referred to as the "Group") and equity account the Group's interest in associates.

The group financial statements have been prepared and approved by the directors in accordance with International Financial Reporting Standards as adopted by the EU ("adopted IFRS").

 

Consolidation

Subsidiaries are entities controlled by the Group. Control exists when the Group has the power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases.

Associates are those entities in which the Group has significant influence, but not control, over the financial and operating policies. The consolidated financial statements include the Group's share of the total recognised income and expense of associates on an equity accounted basis, from the date that significant influence commences until the date that significant influence ceases.

 

Going concern

The Group has considerable financial resources at its disposal and the directors have considered the current financial projections. As a consequence, the directors believe that the Group is well placed to manage its business risks successfully.

After making enquiries, the directors have a reasonable expectation that the Company and the Group have adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the Annual report and accounts.

 

New, revised or changes to existing accounting standards

IAS1 (revised) 'Presentation of financial statements' became effective 1st January 2009. The revision has resulted in minor changes to the presentation of the primary statements.

 

IFRS 8 'Operating segments' became effective on 1st January 2009. This new standard has resulted in changes to segmental reporting from that reported in the 2009 Annual report. Reportable segments have been determined on the basis of the information supplied to the Board for the purposes of assessing performance and the allocation of resources.

Amendments to IAS 32 'Presentation', IAS 39 ' Financial instruments', IFRS 7 'Financial instruments: Disclosures' and IAS 27 ' Consolidated and separate financial statements' became effective before the year end and have not had a material impact on the Group.

 

IFRS 3 'Business combinations (revised)' became effective on 1st July 2009 and results in acquisition costs being expensed, rather than included within the cost of the investment. This change has not had a material impact on the financial statements.

 

IAS 23 'Borrowing costs' amendment became effective on 1st January 2009 and requires borrowing costs which meet certain criteria to be capitalized. The Group does not currently have any material borrowing or interest costs.

 

IFRIC 14, IAS 19, 'The Limit on a Defined Benefit Asset Minimum Funding Requirements and their interaction' provides guidance on assessing the limit in IAS 19 on the amount of surplus that can be recognised as an asset.  It also explains how the pension asset or liability may be affected by a statutory minimum funding requirement. This interpretation became effective for this year, and it has not had a material impact on the financial statements.

 

IFRIC 16 'Hedges of a Net Investment in a Foreign Operation' provides guidance on identifying the foreign currency risks that qualify as a hedged risk in the hedge of a net investment in a foreign operation; where, within a group, hedging instruments that are hedges of a net investment in a foreign operation can be held to qualify for hedge accounting; and how an entity should determine the amounts to be reclassified from equity to profit or loss for both the hedging instrument and the hedged item. This interpretation became effective for this year, and it has not had a material impact on the financial statements.

 

IAS 24 'Related party disclosures' clarifies the definition of related parties and becomes effective from 1st January 2011. This is not expected to have a material effect on the financial statement disclosures.

 

 

  

2.             SEGMENTAL ANALYSIS

 

Renishaw manages its operations in two segments, comprising metrology and healthcare products. The results of these segments are regularly reviewed by the Board to allocate resources to segments and to assess their performance. The Group evaluates performance of the segments on the basis of revenue and profits. The revenue, depreciation and amortisation, and operating profit for each operating segment was:

 

Year ended 30th June 2010

Metrology

Healthcare

Total

 

£'000

£'000

£'000

 




Revenue

162,118

19,489

181,607

 




Depreciation and amortisation

12,725

1,745

14,470

 




Operating profit before exceptional item

31,537

(3,442)

28,095

Exceptional item - Impairment write-off

(1,668)

-

(1,668)

Share of profits from associates

479

-

479

Net financial income



151

 




Profit before tax



27,057

 




Year ended 30th June 2009

Metrology

Healthcare

Total

 

£'000

£'000

£'000

 




Revenue

152,894

18,353

171,247

 




Depreciation and amortisation

12,415

2,349

14,764

 




Operating profit before exceptional item

10,315

(4,324)

5,991

Exceptional item - Redundancy costs

(3,808)

(313)

(4,121)

Share of profits from associates

317

-

317

Net financial income



2,535

 




Profit before tax



4,722

 

There is no allocation of assets and liabilities to operating segments. Depreciation is included within certain other overhead expenditure which is allocated to segments on the basis of the level of activity.

 

The analysis of revenue by geographical market was:

 


2010 at 2009


 

2010

Exchange rates

2009

 

£'000

£'000

£'000

 




Far East

71,051

65,904

52,006

Continental Europe

52,147

51,297

63,222

North and South America

41,455

39,359

40,071

United Kingdom

10,650

10,650

11,259

Other regions ("ROW")

6,304

6,268

4,689

 




Total group revenue

181,607

173,478

171,247

 

Revenue in the above table has been allocated to regions based on the geographical location of the customer. Individual countries which comprised more than 10% of group revenue were:

 


2010

2009

 


£'000

£'000

 




USA


35,381

34,795

China


34,211

19,458

Germany


23,042

28,385

Japan


19,552

20,946

 




 

There was no revenue from transactions with a single customer amounting to 10% or more of the Group's total revenue.

 

The following table shows the analysis of non-current assets by geographical region:

 


2010

2009

 


£'000

£'000

 




United Kingdom


71,660

76,098

Overseas


36,639

36,273

 




Total non-current assets


108,299

112,371

 

 

3.             FINANCIAL INCOME AND EXPENSES

 

 


2010

2009

Financial income


£'000

£'000

 




Expected return on assets in the pension schemes


5,671

7,593

Bank interest receivable


255

1,161

 




Total financial income


5,926

8,754

 




Financial expenses




 




Interest on pension scheme liabilities


5,597

5,964

Bank interest payable


178

255

 




Total financial expenses


5,775

6,219

 

 

4.             INCOME TAX EXPENSE

 

 


2010

2009

 


£'000

£'000

Current tax:




UK corporation tax on profits for the year


14

-

Overseas tax on profits for the year


3,187

3,415

Adjustments for prior years


1,800

-

 




Total current tax


5,001

3,415

 




Deferred tax




Origination and reversal of other temporary differences


744

(2,291)

 




Tax charge on profit


5,745

1,124

 




Effective tax rate (based on profit before tax)


21%

24%

 

The tax for the year is lower (2009 lower) than the UK standard rate of corporation tax of 28% (2009 28%). The differences are explained as follows:

 


2010

2009

 


£'000

£'000

 




Profit before tax


27,057

4,722

 




Tax at 28% (2009 28%)


7,576

1,322

 




Effects of:




Different tax rates applicable in overseas subsidiaries


(3,437)

(1,397)

Research and development tax credit


(1,376)

(1,471)

Adjustments for prior years


1,800

-

Expenses not deductible for tax purposes


231

80

Companies with unrecognised tax losses


495

2,525

Exceptional item with no tax effect


467

-

Other differences


(11)

65

 




Tax charge on profit


5,745

1,124

 

The tax calculations do not account for the reduction in the UK corporation tax rate from 28% to 27%, to come into effect on 1st April 2011.

 

 

 

5.             EARNINGS PER SHARE

 

Basic and diluted earnings per share are calculated on earnings of £21,312,000 (2009 £3,598,000) and on 72,788,543 shares, being the number of shares in issue during both years. There is no difference between the weighted average earnings per share and the basic and diluted earnings per share.

 

 

 

 

 

6.             PROPERTY, PLANT AND EQUIPMENT

 


Freehold



Assets in the



land and

Plant and

Motor

course of



buildings

equipment

vehicles

construction

Total

Year ended 30th June 2010

£'000

£'000

£'000

£'000

£'000







Cost






At 1st July 2009

65,066

76,133

5,129

480

146,808

Additions

512

1,431

496

429

2,868

Transfers

-

460

-

(460)

-

Disposals

-

(882)

(729)

-

(1,611)

Currency adjustment

2,411

265

163

-

2,839







At 30th June 2010

67,989

77,407

5,059

449

150,904







Depreciation






At 1st July 2009

13,541

56,226

3,458

-

73,225

Charge for the year

1,417

5,766

724

-

7,907

Released on disposals

-

(805)

(647)

-

(1,452)

Currency adjustment

333

273

86

-

692







At 30th June 2010

15,291

61,460

3,621

-

80,372







Net book value












At 30th June 2010

52,698

15,947

1,438

449

70,532







At 30th June 2009

51,525

19,907

1,671

480

73,583

 

At 30th June 2010, properties with a net book value of £23,393,000 (2009 £23,815,000) were subject to a registered charge to secure the UK defined benefit pension scheme liabilities.

 

Additions to assets in the course of construction of £429,000 (2009 £862,000) comprise £95,000 (2009 £136,000) for freehold land and buildings and £334,000 (2009 £726,000) for plant and equipment.

 

 

 

7.             INTANGIBLE ASSETS

 

 




Internally

Software licences




Other

generated


In the



Goodwill on

intangible

development


course of



consolidation

assets

costs

In use

acquisition

Total

Year ended 30th June 2010

£'000

£'000

£'000

£'000

£'000

£'000








Cost







At 1st July 2009

5,569

5,416

28,973

11,252

-

51,210

Additions

-

50

6,968

17

117

7,152

Currency adjustment

-

-

-

2

-

2








At 30th June 2010

5,569

5,466

35,941

11,271

117

58,364








Amortisation







At 1st July 2009

-

1,150

15,829

6,548

-

23,527

Charge for the year

-

653

4,692

878

-

6,223

Currency adjustment

-

-

-

1

-

1








At 30th June 2010

-

1,803

20,521

7,427

-

29,751








Net book value














At 30th June 2010

5,569

3,663

15,420

3,844

117

28,613








At 30th June 2009

5,569

4,266

13,144

4,704

-

27,683

 

 

Goodwill acquired has arisen on the acquisition of a number of businesses and has an indeterminable useful life. Therefore it is not amortised but is tested for impairment annually and at any point during the year when an indicator of impairment exists. Goodwill is allocated to the Group's cash generating units (CGUs), which are currently the statutory entities acquired. This is the lowest level in the Group at which goodwill is monitored for impairment and is at a lower level than the Group's operating segments.

 

 

 

 

 

The analysis of acquired goodwill on consolidation is:

 


2010

2009

 


£'000

£'000

 




Acquisition of itp GmbH


2,372

2,372

Acquisition of Renishaw Diagnostics Limited (84.8%)(2009 75%)


1,784

1,784

Acquisition of Renishaw Mayfield SA (75%)


1,215

1,215

Acquisition of PulseTeq Limited (75%)


198

198

 




Total acquired goodwill


5,569

5,569

 

The recoverable amounts of acquired goodwill are based on value in use calculations. These calculations use cash flow projections with assumptions as follows:

 

itp GmbH  (part of the metrology reportable segment)- actual operating results and an average growth rate of 5% for 5 years with a nil terminal growth rate (2009 same basis).

 

Renishaw Diagnostics Limited, PulseTeq Limited and Renishaw Mayfield SA (all in the healthcare reportable segment) - 5 year business plans with a nil terminal growth rate (2009 same basis).

 

A pre-tax discount rate of 12% has been used in discounting the projected cash flows of itp GmbH  (2009 13%) and 15% for Renishaw Diagnostics Limited (2009 13%), PulseTeq Limited (2009 13%) and Renishaw Mayfield SA (2009 13%). These have been set on the basis of these being appropriate rates for a market participant. On this basis, no impairment write downs are required. There is significant headroom in all the above and for an impairment to arise, there would need to be a significant material deterioration in business; this is considered to be remote. An increase in 5% in the discount rate would not result in an impairment.

 

 

8.             INVESTMENT IN ASSOCIATES

 

The Group has the following investments in associates (all investments being in the ordinary share capital of the associate), whose accounting years end on 30th June unless otherwise stated:

 

 


Ownership

Ownership

 

Country of

2010

2009

 

incorporation

%

%

 




RLS merilna tehnika d.o.o.

Slovenia

50

50

Metrology Software Products Limited

England & Wales

50

50

Delcam plc (31st December)

England & Wales

20

20

 




 

Delcam plc is listed on AIM at the London Stock Exchange. Its share price on 30th June 2010 was £2.40 (2009 £2.40). The Company holds 1,524,052 shares.

 

Movements during the year were:

 


2010

2009

 


£'000

£'000

 




Balance at the beginning of the year


7,085

6,788

 




Investments made during the year


-

400

Dividends received


(80)

(80)

Share of profits of associates


479

317

Amortisation of intangibles


(340)

(340)

Other comprehensive income and expense


(324)

-

Impairment of investment in Delcam plc


(1,668)

-

 




Balance at the end of the year


5,152

7,085

 

During the year, the Board decided to write down its investment of Delcam plc, originally purchased at a price of £4.00 per share (whose results are reported as part of the metrology reporting segment), to reflect the prevailing share price of £2.40 as at 30th June 2010. An impairment charge of £1,668,000 is shown as an exceptional item in the Consolidated income statement.

 

Summarised aggregated financial information for associates:

 


2010

2009

 


£'000

£'000

 




Revenue


8,185

7,922

Share of profits for the year


479

317

Assets


7,344

7,011

Liabilities


3,432

2,934

 




 

 

9.             DEFERRED TAX ASSETS AND LIABILITIES

 

Balances at the end of the year were:


2010

2009


Assets

Liabilities

Net

Assets

Liabilities

Net


£'000

£'000

£'000

£'000

£'000

£'000








Property, plant and equipment

-

(3,760)

(3,760)

-

(2,817)

(2,817)

Intangible assets

860

(4,879)

(4,019)

-

(4,241)

(4,241)

Intragroup trading (inventory)

5,309

-

5,309

3,952

-

3,952

Pension schemes

9,694

-

9,694

5,701

-

5,701

Other

4,193

(6,794)

(2,601)

4,512

(3,560)

952








Balance at the end of the year

20,056

(15,433)

4,623

14,165

(10,618)

3,547

 

The movements in the deferred tax balance during the year were:

 


2010

2009

 


£'000

£'000

 




Balance at the beginning of the year


3,547

(2,357)

 




Movements in the Consolidated income statement


(744)

2,291

 




Movement in the cash flow hedging reserve


(2,173)

452

Movement in relation to the pension schemes


3,993

3,161

 




Total movement in the Consolidated statement of comprehensive income and expense


1,820

3,613

 




Balance at the end of the year


4,623

3,547

 

No deferred tax asset has been recognised in respect of tax losses carried forward of £5,513,000 (2009 £3,518,000) due to the uncertainty over their recoverability.

 

 

 

10.          DERIVATIVES

 

Derivatives (non-current assets) of £4,002,000 (2009 £4,020,000) comprise the fair value of outstanding forward contracts with positive fair values, which mature after more than one year. Derivatives (current assets) of £1,158,000 (2009 £709,000) comprise the fair value of outstanding forward contracts with positive fair values, which mature within one year.

Derivatives (non-current liabilities) of £1,575,000 (2009 £6,627,000) comprise the fair value of outstanding forward contracts with negative fair values, which mature after more than one year. Derivatives (current liabilities) of £3,346,000 (2009 £5,623,000) comprise the fair value of outstanding forward contracts with negative fair values, which mature within one year.

 

 

11.          EMPLOYEE BENEFITS

 

The Group operates a number of pension schemes throughout the world. The major scheme, which covers the UK-based employees, was of the defined benefit type. In 2007, this scheme, along with the Irish defined benefit scheme, ceased any future accrual for current members and both were closed to new members. UK and Irish employees are now covered by defined contribution schemes.

The total pension cost of the Group for the year was £4,983,000 (2009 £5,944,000), of which £125,000 (2009 £140,000) related to directors and £1,516,000 (2009 £1,657,000) related to overseas schemes.

The latest full actuarial valuation of the UK defined benefit scheme was carried out at September 2006 and updated to 30th June 2010 by a qualified independent actuary. The major assumptions used by the actuary for the UK and Irish schemes were:

 

 



2010


2009


UK scheme

Irish scheme

UK scheme

Irish scheme






Rate of increase in pension payments

3.3%

2.4%

3.3%

2.5%

Discount rate

5.3%

4.4%

6.2%

5.5%

Inflation rate

3.4%

2.4%

3.4%

2.5%

Expected return on equities

8.1%

7.1%

8.3%

7.4%

Retirement age

64

65

64

65






 

The mortality assumption adopted for 2010 is PCA00, year of birth, medium cohort (2009 short cohort), which reflects the increasing life expectancy.

 

The assets and liabilities in the defined benefit schemes at the end of the year were:

 


2010

2009

 


£'000

£'000

Market value of assets:




Equities


81,737

68,538

Bonds and cash


1,447

1,630

 




 


83,184

70,168

 




Actuarial value of liabilities


(120,435)

(92,626)

 




(Deficit) in the schemes


(37,251)

(22,458)

 




Deferred tax thereon


9,694

5,701

 

The expected rates of return on each asset category are based on market conditions at 30th June 2010 and represent the best estimate of future returns, allowing for risk premiums where appropriate.

 

The movements in the schemes' assets and liabilities were:

 

Assets

Liabilities

Total

Year ended 30th June 2010

£'000

£'000

£'000

 




Balance at the beginning of the year

70,168

(92,626)

(22,458)

Expected return on pension schemes' assets

5,671

-

5,671

Interest on pension schemes' liabilities

-

(5,597)

(5,597)

Actuarial gain/(loss)

7,345

(22,212)

(14,867)

 




Balance at the end of the year

83,184

(120,435)

(37,251)

 

Under the defined benefit deficit funding plan, there are no contributions expected to be made in the year ending 30th June 2011. There are certain UK properties, owned by Renishaw plc, which are subject to a registered charge to secure the UK defined benefit pension scheme liabilities. The Trustees have the right to enforce the charge to recover any deficit if an insolvency event occurs in relation to the Company before 30th September 2016 or if the Company has not made good any deficit by midnight on 30th September 2016. No scheme assets are invested in the Group's own equity. The valuation of the liability applying IFRIC 14 does not give a higher value to the liability than that accounted for.

 

Defined contribution pension liabilities

The Group makes contributions to a number of defined contribution plans around the world to provide benefits for employees upon retirement. The total expense relating to these plans in the year was £4,983,000 (2009 £5,944,000).

 

 

12.          INVENTORIES

 

An analysis of inventories at the end of the year was:

 


2010

2009

 


£'000

£'000

 




Raw materials


13,409

12,335

Work in progress


7,107

5,606

Finished goods


10,368

11,215

 




Balance at the end of the year


30,884

29,156

 

During the year, the amount of inventories recognised as an expense in the Consolidated income statement was £59,310,000 (2009 £61,386,000) and the amount of write-down of inventories recognised as an expense in the Consolidated income statement was £434,000 (2009 £1,335,000).

 

 

13.          PROVISIONS

 

Warranty provision

 

Movements during the year were:

 


2010

2009

 


£'000

£'000

 




Balance at the beginning of the year


656

824

 




Utilised during the year


(599)

(769)

Created during the year


482

601

 




 


(117)

(168)

 




Balance at the end of the year


539

656

 

The warranty provision has been calculated on the basis of historical return-in-warranty information and other internal reports. It is expected that most of this expenditure will be incurred in the next financial year and all expenditure will be incurred within three years of the balance sheet date.

 

 

14.          OTHER PAYABLES

 

Balances at the end of the year were:

 


2010

2009

 


£'000

£'000

 




Payroll taxes and social security


3,081

3,955

Other creditors and accruals


11,946

3,761

 




Total other payables


15,027

7,716

 

 

15.          OTHER PAYABLES (NON-CURRENT)

 

The deferred consideration of £1,222,000 (2009 £1,222,000) is in respect of the investment in Renishaw Diagnostics Limited, which is payable over a five-year period from the date of the initial investment.

 

16.          CAPITAL AND RESERVES

 

Share capital

 

 


2010

2009

 


£'000

£'000

 




Allotted, called-up and fully paid




72,788,543 ordinary shares of 20p each


14,558

14,558

 

The ordinary shares are the only class of share in the Company. Holders of ordinary shares are entitled to vote at general meetings of the Company and receive dividends as declared. The Articles of Association of the Company do not contain any restrictions on the transfer of shares nor on voting rights.

 

Currency translation reserve

 

The currency translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of the foreign operations, offset by foreign exchange differences on bank liabilities which have been accounted for directly in equity on account of them being classified as hedging items.

 

 

Cash flow hedging reserve

 

The cash flow hedging reserve comprises all foreign exchange differences arising from the valuation of forward exchange contracts which are effective hedges and mature after the year end. These are valued on a mark-to-market basis, are accounted for directly in equity and are recycled through the Consolidated income statement when the hedged item affects the Consolidated income statement. The forward contracts mature over the next three and a half years.

 

Movements during the year were:

 


2010

2009

 


£'000

£'000

 




Balance at the beginning of the year


(5,415)

(4,252)

Amounts transferred to the Consolidated income statement


3,538

1,395

Revaluations during the year


2,049

(2,558)

 




Balance at the end of the year


172

(5,415)

  

 

Dividends paid

 

Dividends paid comprised:

 


2010

2009

 


£'000

£'000

 




2008 final dividend paid of 17.63p per share


-

12,833

Interim dividend paid of 4.00p per share (2009 7.76p, net of waivers in 2009)


2,912

2,816

 




Total dividends paid


2,912

15,649

 

A final dividend in respect of the current financial year of 13.6p per share is proposed, to be paid on 18th October 2010 to shareholders on the register on 17th September 2010, with an ex-dividend date of 15th September 2010.

 

 

Non-controlling interest

 

Movements during the year were:

 


2010

2009

 


£'000

£'000

 




Balance at the beginning of the year


18

320

Share of investments


52

(29)

Share of loss for the year


(502)

(273)

 




Balance at the end of the year


(432)

18

 

The non-controlling interest represents the Non-controlling shareholdings in Renishaw Diagnostics Limited (15.2%) (2009 75%), PulseTeq Limited (25%) and Renishaw Mayfield SA (25%).

 

 

17.          RELATED PARTIES

 

During the year, associates (RLS merilna tehnika d.o.o., Metrology Software Products Limited and Delcam plc) purchased goods and services from the Group to the value of £199,000  (2009 £168,000) and sold goods and services to the Group to the value of £2,329,000 (2009 £1,990,000). At 30th June 2010, associates owed £169,000 to the Group (2009 £132,000). Associates were owed £144,000 by the Group (2009 £77,000). Dividends of £80,000 were received from associates during the year (2009 £80,000).

No bad debts were incurred during the year. All transactions were on an arm's length basis.

 

18.          POST-BALANCE SHEET EVENT

 

In July 2010, the Group acquired a shareholding of 29% in Measurement Devices Limited, a company incorporated in Scotland and operating in the metrology business. The consideration was £2.3m. An agreement provides for the further purchase of the balance of majority shareholder shares over a period of four years with the price payable based on the earnings of MDL during the relevant period. It is also intended that the shares held by minority shareholders (14%) will be acquired by a court-approved scheme of arrangement.

 

 

 

Enquiries:                             B R Taylor                             01453 524445

A C G Roberts                      01453 524445

 

Registered office:                New Mills, Wotton-under-Edge, Gloucestershire. GL12 8JR

Telephone:                           01453 524524

Registered number:           1106260

Website:                                 www.renishaw.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR EDLFLBDFBBBF

Companies

Renishaw (RSW)
UK 100

Latest directors dealings